Clinical Trial Update: Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for colorectal cancer with peritoneal metastases; current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Peritoneal Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOX
• Irinotecan (Irinotecan)

Snippet

Sponsor: Catharina Ziekenhuis Eindhoven | Conditions: Colorectal Cancer, Peritoneal Metastases | Phase 2 | Status: UNKNOWN